Description and Brand Names
药物信息提供方：IBM Micromedex
Descriptions
Capmatinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer (NSCLC) in patients whose tumors have an abnormal mesenchymal epithelial transition (MET) gene. Your doctor will perform a test to check for the MET gene before you use this medicine.
Capmatinib belongs to the group of medicines called antineoplastics (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: March 01, 2022
版权 © 2020 IBM Watson Health。保留所有权利。信息仅供终端用户使用，不得出售、重新分发或用于其他商业目的。